Overview

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy of corneal collagen crosslinking (CXL) combined with Intacs for the treatment of keratoconus and corneal ectasia. The goal of CXL is to decrease the progression of keratoconus, while Intacs has been shown to decrease corneal steepness in keratoconus. This study will attempt to determine the relative efficacy of the two procedures either performed at the same session versus CXL performed 3 months after Intacs.
Phase:
Phase 3
Details
Lead Sponsor:
Cornea and Laser Eye Institute
Treatments:
Riboflavin